References
- Chaney MA, Devin Roberts J, Wroblewski K, Shahul S, Gaudet R, Jeevanandam V. Protamine administration via the ascending aorta may prevent cardiopulmonary instability. J Cardiothorac Vasc Anesth. 2016;30:647–655. doi:10.1053/j.jvca.2015.11.014
- Brück S, Skrabal C, Träger K, Reinelt H. Risk factors for adverse reactions after protamine administration in adult patients undergoing cardiac surgery - a case report and literature review. Anasthesiol Intensivmed Notfallmed Schmerzther. 2014;49:360–366. doi:10.1055/s-0034-1383887
- Sokolowska E, Kalaska B, Miklosz J, Mogielnicki A. The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol. 2016;12:897–909. doi:10.1080/17425255.2016.1194395
- Bruins P, Te Velthuis H, Eerenberg-Belmer AJ, et al. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost. 2000;84:237–243. doi:10.1055/s-0037-1614002
- Kimmel SE, Sekeres M, Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg. 2002;94:1402–1408. doi:10.1097/00000539-200206000-00005
- Guan Z, Shen X, Zhang YJ, et al. Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiacsurgery. Medicine. 2018;97:e10908. doi:10.1097/MD.0000000000010908
- Ding XF, Zhong LL, Zhang B, Li J. [Protective effects of lidocaine on hyperoxia-exposed type II alveolar epithelial cells from premature rats]. Zhongguo Dang Dai Er Ke Za Zhi. 2011;13:313–316. [Chinese]
- Cardiovascular physicians branch of Chinese medical association. Chinese experts agreed on the diagnosis and treatment of pulmonary hypertension associated with congenital heart disease in 2015. Chin J Intervent Cardiol. 2015;23:61–69..
- Kim JB, Kim JH, Song KS. Catastrophic bronchial spasm due to a severe anaphylactic reaction to protamine. Korean J Thorac Cardiovasc Surg. 2016;49:472–474. doi:10.5090/kjtcs.2016.49.6.472
- Kimmel SE, Sekeres MA, Berlin JA, Ellison N, DiSesa VJ, Strom BL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. J Am Coll Cardiol. 1998;32:1916–1922. doi:10.1016/S0735-1097(98)00484-7
- Morel DR, Zapol WM, Thomas SJ, et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology. 1987;66:597–604. doi:10.1097/00000542-198705000-00002
- Cui W, Lapointe M, Gauvreau D, Kalant D, Cianflone K. Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol Immunol. 2009;46:3207–3217. doi:10.1016/j.molimm.2009.08.013
- Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology. 2002;97:837–841. doi:10.1097/00000542-200210000-00014
- Ramzan R, Michels S, Weber P, et al. Protamine sulfate induces mitochondrial hyperpolarization and a subsequent increase in reactive oxygen species production. J Pharmacol Exp Ther. 2019;370:308–317. doi:10.1124/jpet.119.257725
- Jastrzebski J, Sykes MK, Woods DG. Cardio-respiratory effects of protamine sulfate in man. Thorax. 1974;29:534–538. doi:10.1136/thx.29.5.534
- Cassuto J, Sinclair R, Bonderovic M. Anti-inflammatory properties of local anesthetics and their present and potential clinical implications. Acta Anaesthesiol Scand. 2006;50:265–282. doi:10.1111/j.1399-6576.2006.00936.x
- Feng G, Liu S, Wang GL, Liu GJ. Lidocaine attenuates lipopolysaccharide induced acute lung injury through inhibiting NF-kappaB activation. Pharmacology. 2008;81:32–40. doi:10.1159/000107792
- Satoh K, Kamada S, Kumagai M, Sato M, Kuji A, Joh S. Effect of lidocaine on swine lingual and pulmonary arteries. J Anesth. 2015;29:529–534. doi:10.1007/s00540-014-1965-9